NPS Announces Progression of the Calcilytics Development Program in Osteoporosis by GlaxoSmithKline

    PARSIPPANY, N.J., June 4 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:  
NPSP) today announced that GlaxoSmithKline (GSK), under a collaboration
agreement between the two companies, has dosed the first patient in a Phase II
dose-range finding study with the investigational calcilytic compound 751689
in post-menopausal women with osteoporosis.
    The Phase II, double blind, placebo-controlled study will evaluate the
efficacy and safety of compound 751689 over a twelve month period.  The study
will enroll approximately 520 post-menopausal women with osteoporosis and is
designed to assess the overall efficacy, safety, and tolerability of 751689 in
comparison with placebo and two active comparators.  Outcome measures include
bone mineral density of the lumbar spine and hip, vertebral and hip strength
parameters, and biomarkers of bone turnover.  Data from this study, along with
other data, will be used to select a dose of compound 751689 for further
    NPS CEO and president, Tony Coles, M.D., stated, "We are pleased that the
development of the calcilytics program is advancing under GSK's leadership. We
believe that calcilytics have the potential to represent an important new
class of drugs for the treatment of osteoporosis and look forward to the
results of this exciting trial."
    Under the terms of the Collaborative Research and License Agreement with
GSK, NPS will receive royalties on global product sales and has the option to
co-promote products resulting from the collaboration with GSK in the United

    Calcilytics are novel small molecules that work by antagonizing
calcium-sensing receptors on the surface of the parathyroid gland, thereby
triggering a transient release of the body's own stores of parathyroid hormone
(PTH).  This release of PTH may have the potential to rebuild the bone mass
lost as a result of osteoporosis and improve overall bone microarchitecture in
these patients.   NPS and GSK have previously disclosed that in animal models,
daily oral administration of a calcilytic compound was shown to stimulate new
bone formation, increase bone mineral density (BMD) at vertebral and
non-vertebral skeletal sites, and increase biomechanical parameters of bone

    NPS Pharmaceuticals is engaged in the discovery, development and
commercialization of therapeutic small molecules and recombinant proteins to
treat bone and mineral and gastrointestinal disorders.
    NPS's first approved product, cinacalcet HCl, is marketed in the United
States by Amgen under the brand name Sensipar(R) as a treatment for secondary
hyperparathyroidism. NPS partner Kirin is developing cinacalcet HCl as a
treatment for this condition in Japan.
    The company's Phase 3 drug candidates are PREOS(R) (parathyroid hormone
[rDNA origin] for injection) for the treatment of osteoporosis, and
teduglutide for gastrointestinal disorders including Short Bowel Syndrome.
Teduglutide has been granted orphan drug status in the United States and
Europe for this condition.
    The company's earlier-stage drug candidates include antagonists of
metabotropic glutamate receptors to treat neurological and psychiatric
conditions (partner: AstraZeneca), and glycine reuptake inhibitors to treat
schizophrenia (partner: Johnson & Johnson).  Additional information is
available on the company's website,

    Cautionary Statement for the Purpose of the "Safe Harbor" Provisions
           of the Private Securities Litigation Reform Act of 1995

    Note: Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. Such risks and uncertainties include:  drug candidates under our
calcilytics collaboration with GlaxoSmithKline (GSK) may not prove to be safe
or efficacious in future clinical trials and the FDA may delay approval or may
not approve such drug candidates; we are entirely dependent upon  GSK for the
development and commercialization of drug candidates under our calcilytics
collaboration; and if GSK does not devote adequate resources to the
development and commercialization of our partnered drug candidates, completion
of clinical trials and the commercialization of any approved drug candidate
would be delayed.  All information in this press release is as of May 23,
2007, and we undertake no duty to update this information. A more complete
description of these risks can be found in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K  for the year
ended December 31, 2006, and our Quarterly Report on Form 10-Q for the
quarter-ended March 31, 2007.

For further information:

For further information: Brandi Simpson, Sr. Director, Investor
Relations  of NPS Pharmaceuticals, Inc., +1-801-883-2397 Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890